Partnership will enable the identification of potential therapeutic candidates for autoimmune diseases in Microba’s extensive strain bank.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Three key opinion leaders will make much-needed advancements in treatment options for Inflammatory Bowel Disease on new advisory panel.
A/Prof Lutz Krause and Dr David Wood discuss practical applications of metagenomics in microbiome discovery at ASM's Annual Scientific Meeting.
Professor Hugenholtz will discuss approaches to using new tools and data in research and explain the different approaches to taxonomic classification.
A/Prof Krause will discuss the human-first, data-driven approach to therapeutic discovery that Microba employs in their IBD therapeutic program.
Microba launched an IBD Research and Development (R&D) program in 2019 to tackle IBD by mining the gut microbiome for novel biotherapeutics.
Microba has backed sufferers of IBD through a donation to support IBD organisation Crohn’s and Colitis Australia.
Improved therapies for the long-term management of IBD are crucial and a currently unmet clinical need.